NKTR-255

DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.

DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.

Nektar Therapeutics and TrialNet have announced a collaboration to evaluate rezpegaldesleukin, a first-in-class T regulatory cell stimulator, in patients with new-onset type 1 diabetes.

The FDA has granted Fast Track designation to rezpegaldesleukin for moderate-to-severe atopic dermatitis in patients 12 years and older.

The FDA granted priority review to Nuvation Bio's NDA for taletrectinib, a next-generation ROS1 inhibitor, for advanced ROS1+ non-small cell lung cancer, setting a PDUFA date of June 23, 2025.